Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Microenvironment-Derived Regulation of HIF Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme

(2018) Dieter Henrik Heiland et al.   MOLECULAR CANCER RESEARCH

OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

(2017) D. A. Reardon et al.   NEURO-ONCOLOGY

Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme

(2017) Sabrina Heynckes et al.   Oncotarget

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme

(2017) Dieter Henrik Heiland et al.   Oncotarget

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

(2017) Anna C. Filley et al.   Oncotarget

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Immune Checkpoint in Glioblastoma: Promising and Challenging

(2017) Jing Huang et al.   Frontiers in Pharmacology

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Origin of the U87MG glioma cell line: Good news and bad news

(2016) Marie Allen et al.   Science Translational Medicine

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance

(2015) So Mee Kwon et al.   PLoS One

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

RNA-seq of 272 gliomas revealed a novel, recurrentPTPRZ1-METfusion transcript in secondary glioblastomas

(2014) Zhao-Shi Bao et al.   GENOME RESEARCH

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

The epidemiology of glioma in adults: a "state of the science" review

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Epidemiology of glial and non-glial brain tumours in Europe

(2012) Emanuele Crocetti et al.   EUROPEAN JOURNAL OF CANCER

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma

(2009) Ryo Yamamoto et al.   CANCER SCIENCE

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY